Overview
Precursor of epinephrine that is secreted by the adrenal medulla and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers and of the diffuse projection system in the brain arising from the locus ceruleus. It is also found in plants and is used pharmacologically as a sympathomimetic.
Background
Precursor of epinephrine that is secreted by the adrenal medulla and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers and of the diffuse projection system in the brain arising from the locus ceruleus. It is also found in plants and is used pharmacologically as a sympathomimetic.
Indication
Mainly used to treat patients in vasodilatory shock states such as septic shock and neurogenic shock and has shown a survival benefit over dopamine. Also used as a vasopressor medication for patients with critical hypotension.
Associated Conditions
- Cardiac Arrest
- Severe hypotension
- Shock
- Acute, severe Hypotension
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/06/15 | Not Applicable | Recruiting | |||
2025/05/18 | Phase 1 | ENROLLING_BY_INVITATION | Visarat Palitnonkiat | ||
2025/04/10 | Phase 4 | Not yet recruiting | mehmet özkılıç | ||
2025/03/03 | Not Applicable | Not yet recruiting | General and Teaching Hospital Celje | ||
2025/02/25 | N/A | Not yet recruiting | |||
2025/02/20 | Not Applicable | Recruiting | |||
2025/01/31 | Phase 4 | Recruiting | |||
2025/01/22 | N/A | Active, not recruiting | |||
2024/12/24 | Phase 4 | Not yet recruiting | |||
2024/12/02 | Not Applicable | Recruiting |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| NorthStar Rx LLC | 72603-180 | INTRAVENOUS | 1 mg in 1 mL | 12/1/2023 | |
| Baxter Healthcare Company | 43066-997 | INTRAVENOUS | 1 mg in 1 mL | 5/6/2021 | |
| Baxter Healthcare Corporation | 43066-997 | INTRAVENOUS | 1 mg in 1 mL | 5/6/2021 | |
| Hospira, Inc. | 0409-3375 | INTRAVENOUS | 1 mg in 1 mL | 10/31/2020 | |
| HF Acquisition Co LLC, DBA HealthFirst | 51662-1315 | INTRAVENOUS | 1 mg in 1 mL | 2/5/2021 | |
| Cantrell Drug Company | 52533-166 | INTRAVENOUS | 32 ug in 1 mL | 3/6/2015 | |
| Hospira, Inc. | 0409-1443 | INTRAVENOUS | 1 mg in 1 mL | 10/31/2020 | |
| WG Critical Care, LLC | 44567-640 | INTRAVENOUS | 0.016 mg in 1 mL | 7/31/2023 | |
| Par Pharmaceutical, Inc. | 42023-247 | INTRAVENOUS | 16 mg in 250 mL | 10/20/2022 | |
| Mylan Institutional LLC | 67457-852 | INTRAVENOUS | 1 mg in 1 mL | 10/22/2018 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| NORADRENALINE SINTETICA CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML | SIN16622P | INFUSION, SOLUTION CONCENTRATE | 1.000mg/ml | 10/5/2022 | |
| NOREPINEPHRINE KALCEKS CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML | SIN16733P | INFUSION, SOLUTION CONCENTRATE | 1.0mg/mL | 3/3/2023 | |
| NORADRENALINE AGUETTANT 1MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION | SIN15593P | INFUSION, SOLUTION CONCENTRATE | 1mg/ml | 12/4/2018 | |
| LEVOPHED INJECTION 1 mg/ml | SIN05754P | INJECTION | 1 mg/ml | 4/8/1991 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Norepinephrine Bitartrate Injection | 国药准字H20258042 | 化学药品 | 注射剂 | 3/25/2025 | |
| Norepinephrine Bitartrate Injection | 国药准字H20254039 | 化学药品 | 注射剂 | 4/30/2025 | |
| Norepinephrine Bitartrate Injection | 国药准字H20243326 | 化学药品 | 注射剂 | 3/12/2024 | |
| Norepinephrine Bitartrate Injection | 国药准字H44022396 | 化学药品 | 注射剂 | 5/6/2020 | |
| Norepinephrine Bitartrate Injection | 国药准字H20247146 | 化学药品 | 注射剂 | 6/28/2024 | |
| Norepinephrine Bitartrate Injection | 国药准字H42021301 | 化学药品 | 注射剂 | 8/27/2020 | |
| Norepinephrine Bitartrate Injection | 国药准字H20244335 | 化学药品 | 注射剂 | 6/28/2024 | |
| Norepinephrine Bitartrate Injection | 国药准字H20217065 | 化学药品 | 注射剂 | 7/30/2021 | |
| Norepinephrine Bitartrate Injection | 国药准字H20249676 | 化学药品 | 注射剂 | 12/1/2024 | |
| Norepinephrine Bitartrate Injection | 国药准字H20247024 | 化学药品 | 注射剂 | 2/5/2024 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| NORADRENALINE AGUETTANT CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/ML | N/A | N/A | N/A | 5/14/2014 | |
| NOREPINEPHRINE TAI YU CONCENTRATE FOR SOLUTION FOR INFUSION 4MG/4ML | N/A | N/A | N/A | 5/22/2024 |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||